Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.
Cross NCP, Ernst T, Branford S, Cayuela JM, Deininger M, Fabarius A, Kim DDH, Machova Polakova K, Radich JP, Hehlmann R, Hochhaus A, Apperley JF, Soverini S. Cross NCP, et al. Among authors: machova polakova k. Leukemia. 2023 Nov;37(11):2150-2167. doi: 10.1038/s41375-023-02048-y. Epub 2023 Oct 4. Leukemia. 2023. PMID: 37794101 Free PMC article. Review.
miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels.
Musilova K, Devan J, Cerna K, Seda V, Pavlasova G, Sharma S, Oppelt J, Pytlik R, Prochazka V, Prouzova Z, Trbusek M, Zlamalikova L, Liskova K, Kruzova L, Jarosova M, Mareckova A, Kornauth C, Simonitsch-Klupp I, Schiefer AI, Merkel O, Mocikova H, Burda P, Machova Polakova K, Kren L, Mayer J, Zent CS, Trneny M, Evans AG, Janikova A, Mraz M. Musilova K, et al. Among authors: machova polakova k. Blood. 2018 Nov 29;132(22):2389-2400. doi: 10.1182/blood-2018-06-855502. Epub 2018 Sep 13. Blood. 2018. PMID: 30213873 Free article.
Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase.
Machova Polakova K, Kulvait V, Benesova A, Linhartova J, Klamova H, Jaruskova M, de Benedittis C, Haferlach T, Baccarani M, Martinelli G, Stopka T, Ernst T, Hochhaus A, Kohlmann A, Soverini S. Machova Polakova K, et al. J Cancer Res Clin Oncol. 2015 May;141(5):887-99. doi: 10.1007/s00432-014-1845-6. Epub 2014 Nov 4. J Cancer Res Clin Oncol. 2015. PMID: 25367136
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.
Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, Lange T, Lion T, Machova Polakova K, Dulucq S, Martinelli G, Oppliger Leibundgut E, Pallisgaard N, Barbany G, Sacha T, Talmaci R, Izzo B, Saglio G, Pane F, Müller MC, Hochhaus A. Cross NC, et al. Among authors: machova polakova k. Leukemia. 2015 May;29(5):999-1003. doi: 10.1038/leu.2015.29. Epub 2015 Feb 5. Leukemia. 2015. PMID: 25652737 Free PMC article. Review.
Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale.
Cross NC, White HE, Ernst T, Welden L, Dietz C, Saglio G, Mahon FX, Wong CC, Zheng D, Wong S, Wang SS, Akiki S, Albano F, Andrikovics H, Anwar J, Balatzenko G, Bendit I, Beveridge J, Boeckx N, Cerveira N, Cheng SM, Colomer D, Czurda S, Daraio F, Dulucq S, Eggen L, El Housni H, Gerrard G, Gniot M, Izzo B, Jacquin D, Janssen JJ, Jeromin S, Jurcek T, Kim DW, Machova-Polakova K, Martinez-Lopez J, McBean M, Mesanovic S, Mitterbauer-Hohendanner G, Mobtaker H, Mozziconacci MJ, Pajič T, Pallisgaard N, Panagiotidis P, Press RD, Qin YZ, Radich J, Sacha T, Touloumenidou T, Waits P, Wilkinson E, Zadro R, Müller MC, Hochhaus A, Branford S. Cross NC, et al. Among authors: machova polakova k. Leukemia. 2016 Sep;30(9):1844-52. doi: 10.1038/leu.2016.90. Epub 2016 Apr 25. Leukemia. 2016. PMID: 27109508 Free PMC article.
Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients.
Polivkova V, Rohon P, Klamova H, Cerna O, Divoka M, Curik N, Zach J, Novak M, Marinov I, Soverini S, Faber E, Machova Polakova K. Polivkova V, et al. Among authors: machova polakova k. PLoS One. 2016 May 23;11(5):e0155959. doi: 10.1371/journal.pone.0155959. eCollection 2016. PLoS One. 2016. PMID: 27214026 Free PMC article.
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Soverini S, De Benedittis C, Castagnetti F, Gugliotta G, Mancini M, Bavaro L, Machova Polakova K, Linhartova J, Iurlo A, Russo D, Pane F, Saglio G, Rosti G, Cavo M, Baccarani M, Martinelli G. Soverini S, et al. Among authors: machova polakova k. BMC Cancer. 2016 Aug 2;16:572. doi: 10.1186/s12885-016-2635-0. BMC Cancer. 2016. PMID: 27485109 Free PMC article.
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX; EURO-SKI investigators. Saussele S, et al. Among authors: machova polakova k. Lancet Oncol. 2018 Jun;19(6):747-757. doi: 10.1016/S1470-2045(18)30192-X. Epub 2018 May 4. Lancet Oncol. 2018. PMID: 29735299 Clinical Trial.
37 results